Abid Ansari is a finance executive with a 20+ year track record in the life sciences industry encompassing corporate finance, fundraising, business development, and investor relations experiences for public and private life science companies. Previously, he served as CFO of Artios, a Cambridge, United Kingdom-based DNA damage response company where he led the company’s $153 million Series C fund raising.  As CFO of Precision BioSciences (NASDAQ: DTIL), a next generation genome editing company, Abid helped the company raise over $300 million in capital, including a $146 million initial public offering (IPO). Earlier in his career, Abid held positions at GlaxoSmithKline (GSK) in deal finance and portfolio management. While at GSK, he worked on a variety of transactions including the acquisition of the Bristol Myers Squibb (BMS) HIV portfolio, asset sale of ofatumumab to Novartis,  and the research collaboration/licensing deal with Adaptimmune.  Abid also worked at MedImmune LLC in commercial and capital finance roles. Abid Ansari holds a Bachelor of Science degree in chemical engineering and a Master of Business Administration, both from Purdue University.  He is also a CPA.